Pharvaris N.V. is a clinical-stage company dedicated to developing and commercializing oral drugs that target crucial biological pathways that are well-suited to address multiple indications. The company's primary focus is on the development of treatments for patients suffering from hereditary angioedema (HAE), a rare genetic disorder affecting roughly 1 in 10,000 to 1 in 50,000 people globally, which causes episodic yet severe swelling attacks.
Pharvaris was founded in 2015 and is registered in the Netherlands. The company deploys an innovative approach to drug development, leveraging its expertise in small molecule drug discovery and development, specifically focusing on Bruton’s tyrosine kinase (BTK) inhibitor design and synthesis. BTK plays a critical role in the onset of swelling in HAE patients, hence the significance of this line of research.
The company's lead program, PHVS416, utilizes this approach and is a technologically advanced oral formulation of PHA121, a potent and selective BTK inhibitor. PHVS416 is designed to provide effective, rapid, and sustained relief from HAE attacks, hence significantly improving the patients' quality of life. Similarly, Pharvaris is advancing another drug candidate, PHVS719, which is also an orally administered BTK inhibitor targeting HAE prophylaxis.
Pharvaris's commitment to developing oral therapies for HAE stems from the understanding that many patients prefer oral medication. Current treatments for HAE primarily involve intravenous or subcutaneous injections, which can be inconvenient and painful for patients. Aside from making treatments more patient-friendly, the development of orally administered drugs for HAE may also serve to expand the treatment market.
Pharvaris expressed its commitment to drug development for HAE treatment and other potential indications by pointing out that small molecule BTK inhibition, in addition to HAE, holds the potential for therapeutic benefit in a broad range of other diseases, and they are dedicated to exploring these possibilities.
Since its establishment, Pharvaris has equipped itself with a team of scientists possessing extensive experience in the pharmaceutical industry, particularly in the area of small molecule drug discovery and development. With a management team that holds a proven track record in the pharmaceutical industry, Pharvaris is well-positioned to fulfill its mission of developing and commercializing new treatments for patients with significant unmet medical needs.
To summarize, Pharvaris is striving to bring about a paradigm shift in the treatment options for hereditary angioedema and potentially other diseases. They continue to leverage their expertise, innovative approach, and dedication to patient-centric solutions to revolutionize care for HAE patients. As a relatively young company with a robust pipeline, Pharvaris is well-positioned for future growth.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Wall Street analysts project that Pharvaris N.V. (PHVS) could see a 36.16% rally, with a mean price target of $47.75. Despite the consensus, the article cautions against relying solely on price targets, emphasizing that strong agreement among analysts and positive earnings estimate revisions, coupled with a Zacks Rank #2 (Buy), indicate potential upside. Investors are advised to treat price targets with skepticism and consider underlying fundamental drivers.
Pharvaris N.V. (PHVS), a Swiss-based biopharmaceutical company, is highlighted as a compelling investment opportunity in the biotech sector with a potential upside of 53.58%. The company is focused on developing therapies for rare diseases like hereditary angioedema (HAE), with its lead candidate deucrictibant in Phase 3 clinical trials. Despite financial metrics typical of a drug development phase company (negative EPS and free cash flow), strong analyst ratings and promising pipeline developments suggest significant long-term growth potential.
Pharvaris N.V. (PHVS) has published a slide deck discussing the topline results of its Chapter-3 Phase III study for deucrictibant. This study investigates deucrictibant's efficacy as a prophylactic treatment for hereditary angioedema. The information was released by SA Transcripts, which focuses on providing earnings call transcripts and related developments.
Guggenheim has maintained a "Buy" rating for Pharvaris (PHVS) and increased its price target to $44.00 from $40.00, reflecting confidence in the company's growth potential due to advancements in its clinical trials for hereditary angioedema treatments. Despite this positive analyst outlook, Pharvaris has a low GF Score™ of 22/100, indicating significant weaknesses in profitability and growth, alongside notable insider selling activity. Investors are advised to consider these contrasting factors when evaluating PHVS.
Pharvaris N.V. announced an 83% reduction in average monthly hereditary angioedema (HAE) attack rates with once-daily deucrictibant XR, compared to placebo. For patients with Type 1 and Type 2 HAE, the decrease was even higher at 87%. These positive results support the company's plans to seek marketing authorization for deucrictibant XR starting in the first half of 2027.
Pharvaris N.V. announced that its deucrictibant extended-release (XR) tablet achieved an 83% reduction in monthly hereditary angioedema (HAE) attack rates in the pivotal CHAPTER-3 Phase III study. This positive result paves the way for a prophylaxis New Drug Application (NDA) submission in the first half of 2027, complementing an earlier NDA filing for the immediate-release (IR) formulation for on-demand HAE treatment. Deucrictibant aims to be the first oral HAE therapy covering both on-demand and prophylactic needs, with its unique mechanism of blocking the bradykinin B2 receptor.
Pharvaris N.V. (NASDAQ: PHVS) has officially designated its Leiden, Netherlands office as its principal executive location. The company also disclosed significant risks associated with the development of its drug candidate, deucrictibant, which include uncertainties in regulatory approvals, clinical trial outcomes, manufacturing, and market competition. These factors could substantially impact Pharvaris's future financial performance.